FDA approves Hikma’s Vascepa generic

London-based Hikma Pharmaceuticals has won approval to launch the first generic version of Vascepa (icosapent ethyl), after having key Amarin patents for the heart drug invalidated.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

FDA approves Dr Reddy’s Vascepa generic

13 August 2020 Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.

Americas

Fed Circuit affirms generic maker’s win over Eagle

11 May 2020 The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.

Americas

Amarin suffers defeat over Vascepa patents

1 April 2020 A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

FDA approves Hikma’s Vascepa generic

More on this story

Editor's picks

Editor's picks

More features